Summary.
A study of the immunocytochemical localization of acidic fibroblast growth factor (aFGF) in the rat digestive system using a polyclonal anti-aFGF antiserum revealed immunoreactive cells in the periphery of the islets of Langerhans and in the mucosal epithelia of the intestine, from the jejunum through the colon. In the pancreatic islet, light microscopic immunostaining of consecutive sections with anti-aFGF and anti-glucagon antisera as well as pre-embedding immuno-electron microscopy demonstrated that aFGF-like immunoreactivity belongs to the A cell. In the intestinal epithelium, the aFGF-immunoreactive cell was simultaneously reactive to anti-glucagon antiserum and was ultrastructurally identified as the L-cell, which is known to produce glucagon-like immunoreactants derived from proglucagon. Post-embedding immuno-electron microscopy further revealed that the immunoreactivity is localized in the secretory granules of A-and L-cells. These results suggest that an aFGF-like immunoreactant occurs in the populations of gasrto-entero-pancreatic endocrine cells that express proglucagon.
Acidic and basic fibroblast growth factors (aFGF and bFGF; also referred to as FGF1 and FGF2) are prototype members of a family of heparin-binding growth factors (BURGESS and MACIAG, 1989) . They stimulate the proliferation and/or differentiation of many cell types of mesodermal, epithelial and neuroectodermal origin, and are considered to be involved in a wide variety of biological phenomena, including angiogenesis, wound healing, neural growth, and embryogenesis (GOSPODAROWICZ et al., 1986; FOLKMAN and KLAGSBRUN,1987; THOMAS 1987; WAGNER,1991) . Acidic FGF was originally identified in the brain by its ability to induce the proliferation of cultured myoblasts and endothelial cells (GOSPODAROWICZ et al., 1975; MACIAG et al., 1979) . It has been isolated from various mammalian organs, including the brain (THOMAS et al., 1984) , retina (BAIRD et al., 1985) and heart (SASAKI et al., 1989) . A number of studies using immunohistochemistry and in situ hybridization have essentially focused on aFGF produced in the nervous system (TOOYAMA et al., 1991; ELDE et al., 1991; STOCK et al., 1992; BUGRA et al., 1993) .
The digestive system has been paid relatively little attention as a site of aFGF production. Only the liver has been described regarding the production of aFGF in relation to the hepatocyte proliferation (KAN et al., 1989; MARSDEN et al., 1992) . In the present study, we have examined the rat digestive system with immunocytochemistry using a polyclonal antiserum against aFGF. We demonstrate a distinct localization of aFGF-like Immunoreactivity in Subpopulations of endocrine cells in the gastro-entero-pancreatic system, i.e., those producing glucagon and glucagonrelated peptides.
MATERIALS AND METHODS

Antibody
Acidic FGF was purified from an extract of bovine brain by heparin affinity chromatography followed by reverse phase high performance liquid chromatography, accoding to procedures described for purification of aFGF from the bovine heart (SASAKI et al., 1989 A polyclonal antiserum against aFGF was raised in a rabbit by subcutaneously injecting 100-170ug of purified aFGF emulsified with Freund's complete or incomplete adjuvant at 1-week intervals. Injections were repeated four times with the complete adjuvant and another four times with the incomplete adjuvant, and the rabbit was bled 10 days after the final injection. The antiserum was prepared by a conventional method and stored in aliquots at -80C.
Animals and tissue preparation
Male Wistar rats weighing 250-300 g were kept under a 12h-light/12h-dark condition with free access to standard food and water. They were fixed in the morning under Nembutal anesthesia by a transcardial perfusion with cold physiological saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.2). The organs, including the tail portion of the pancreas, the stomach, duodenum, jejunum, ileum and the proximal portion of the colon, were excised and further immersed in the same fixative for 4 h at 4C followed by washing in phosphate buffer. To make paraffin sections for light microscopy, the tissue blocks were dehydrated in a graded ethanol-xylene series and embedded in paraffin at 60C. To make cryosections for light microscopy and pre-embedding immuno-electron microscopy, the tissue blocks were washed with phosphate buffer and cryoprotected by immersion in a 30% sucrose/phosphate buffer overnight at 4C. For post-embedding immuno-electron microscopy, the tissue blocks were cut into small pieces, dehydrated in a graded ethanol series and embedded in LR-White resin (London Resin Co, London, UK) in the presence of 1% benzoyl peroxide. They were then polymerized for 1-2 days at room temperature with an ultraviolet polymerizer.
Western blot analysis
Purified samples of bovine brain aFGF (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and bovine pituitary bFGF (Biomedical Technologies, Inc., Stoughton, MA), each 0.1 jig in amount, were separated by electrophoresis in a 15% acrylamide slab gel at pH 8.8 in the presence of 0.1% SDS according to LAEMMLI (1970) . They were then transferred electro-phoretically to a nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany) according to TOWBIN et al. (1979) . The membrane was incubated overnight at 4C with anti-aFGF antiserum diluted at 1:500 in phosphate buffered saline (PBS). After washing with PBS containing 0.1% Tween 20, the immunoreaction was visualized by incubating the membrane successively at room temperature with a biotinylated anti-rabbit IgG antibody (Vector Laboratories, Inc., Burlingame, CA) diluted at 1:200 in PBS for 1 h, streptavidinconjugated horse radish peroxidase (Dakopatts, Glostrup, Denmark) dilued at 1:500 in PBS for 1 h, and finally with a mixture of 0.01% 3'3'-diaminobenzidine tetrahydrochloride (DAB) and 0.02% hydrogen peroxide in 50 mM Tris-HCI, pH 7.5.
Immunocytochemistry
For light microscopic immunohistochemistry, the cryoprotected tissue blocks were frozen and cut into 15 um sections using a cryostat, and the paraffinembedded tissue blocks were cut into 4um sections using a microtome. The sections were mounted on gelatin-coated glass slides and deparaffinized with xylene-graded ethanol series. They were first treated successively with 0.3% Tween 20 in PBS for 1 h, with 0.3% hydrogen peroxide in methanol for 10 min, and with 5% normal swine serum (Dakopatts) for 30 min. They were then incubated with the primary antisera (anti-aFGF diluted at 1: 500 and anti-glucagon diluted at 1:4000 in PBS) overnight at room temperature. After washing with PBS, the immunoreaction sites were made visible by the biotin-streptavidin procedure, as in Western blotting. Comparison of aFGFimmunoreactive cells with glucagon-immunoreactive cells was performed using either the consecutive paraffin sections or reverse (mirror) consecutive cryosections. For immunohistochemical control, the primary antisera were absorbed overnight at 4C with purified aFGF or glucagon at 50ug/ml prior to the immunostaining.
For electron microscopic immunocytochemistry with the pre-embedding (immuno-peroxidase) method, the immunostained cryosections were postfixed with 0.5% OsO, for 20 min, stained with 0.5% uranium acetate for 30 min, dehydrated with a graded ethanol series, and embedded in an epoxy resin based on Glicidether 100 (Selva Feinbiochemica GmbH & Co, Heidelberg, Germany). Ultrathin sections were made and examined wity an electron microscope (Hitachi H-700) at 100 kV. For electron microscopic immunocytochemistry with the post-embedding (immuno-gold) method, ultrathin sections cut from the LR-White blocks were collected onto nickel grids and, following treatment with 2% bovine serum albumin (BSA) in PBS for 15 min, were incubated with anti-aFGF antiserum overnight at room temperature. After washing with PBS, the sections were subjected to reaction with colloidal gold particle (20 nm diameter)-conjugated anti-rabbit IgG (E-Y Lab, San Mateo, CA) diluted at 1:20 in PBS containing 0.1% BSA for 4 h at room temperature.
They were then stained briefly with uranyl acetate and lead succinate for electron microscopic observation.
RESULTS
Specificity of the antibody
In Western blot analysis, anti-aFGF antiserum reacted with purified aFGF and formed an immunostained protein band of 16 kDa, which corresponded to the known size of aFGF (Fig. 1) . In contrast, the antiserum showed no cross-reaction with purified bFGF. These results verified the antigen specificity of the present anti-FGF antiserum. Endocrine pancreas
In both the cryosections and paraffin sections of the pancreas, a strong immunoreactivity to anti-aFGF antiserum was found in those cells located preferentially at the periphery of the islets of Langerhans (Fig. 2a) . In contrast, no staining was recognized in the rest of the endocrine pancreas or in any portions of the exocrine pancreas. The consecutive paraffin sections incubated with anti-aFGF and anti-glucagon antisera clearly demonstrated the staining of identical cell populations (Fig. 2a, b) . In contrast, immunoreactivity for insulin or somatostatin did not coincide with that for aFGF (data not shown). These results indicated that the aFGF-like immunoreactivity belongs to the A-cell of the endocrine pancreas. To examine the specificity of the immunoreactions, preabsorption of the antisera with excess amounts of purified antigens was performed.
As shown in Figure 3a -e, absorption of anti-aFGF antiserum with aFGF, as well as that of anti-glucagon antiserum with glucagon, completely hindered the immunoreactions.
In contrast, absorption of anti-aFGF antiserum with glucagon caused no suppression of the immunostaining. These results indicate that the present anti-aFGF antiserum specifically recognizes aFGF and does not cross-react with glucagon within A-cells.
To confirm the identification of immunoreactive cell types, the cryostat section of the pancreas immunostained for aFGF was examined with pre-embedding immuno-electron microscopy. The immunopositive islet cells displayed numerous large endocrine granules with a round, homogeneously electrondence core, about 200-300 nm in diameter, surrounded by an electron-lucent halo (Fig. 4) . These ultrastructural features verified the identification of aFGFimmunoreactive cell as the A-cell (BANI SACCHI and BANI, 1985) . No immunoreactivity was recognized in other endocrine cell types or in the exocrine cells. Therefore, the post-embedding immuno-electron microscopic analysis was performed using LR-White sections. As shown in Figure  5a -c, the gold particles representing the immunoreactivity for aFGF were located exclusively in the secretory granules of A-cells, whereas they were neither recognizable in other portions of the cytoplasm nor in the nucleus. Again it was confirmed that B-and D-cells of the islets as well as exocrine acinar cells were devoid of the immunoreaction.
Comparison of the adjacent ultrathin sections of the same A cell immunostained with anti-aFGF and anti-glucagon antisera suggested that an aFGF-like immunoreactant coexists with glucagon in all secertory granules of the A cell (Fig.  5c, d ).
Intestine
In the cryostat sections of the gastro-enteric tract, there was a small number of cells, scattered solitarily in the mucosal epithelia, that were moderately immunoreactive for aFGF (Fig. 6a) . They were scarcely encountered in the stomach and duodenum but occurred at about an equal frequency in the jejunum, ileum and colon. This immunoreactivity was hindered completely by preabsorbing the antiserum with purified aFGF (data not shown). The paraffin sections failed to detect aFGF-like immunoreactivity in the intestine. However, pairs of "mirror" cryosections immunostained with anti-aFGF and anti-glucagon antisera frequently detected cells that were simultaneously reactive to both antisera (Fig. 6a, b) .
Pre-embedding immuno-electron microscopy showed that aFGF-immunoreactive cells as well as glucagon-immunoreactive cells in the intestine have secretory granules that are similar to those of islet A-cells but with cores slightly more irregular in shape and size, and surrounded by narrower haloes (Figs. 7, 8 ). These features of the intestinal aFGFimmunoreactive cell, i.e., their distributional pattern, glucagon-immunoreactivity and ultrastructure, coincided with those of the L-cell, which has been known to produce glucagon-like peptides (RAVAZZOLA et al., 1979) . Post-embedding immuno-electron microscopy further demonstrated that, as in islet A-cells, aFGFlike immunoreactivity is localized primarily in the secretory granules of L-cells (Fig. 9) .
DISCUSSION
In the present study, we have provided evidence of the occurrence of immunoreactive aFGF in distinct endocrine cell populations of pancreatic islets and intestinal epithelia. To our knowledge, no endocrine system has been highlighted as the site for aFGF production. However, growing immunohistochemical evidence supports the idea that the endocrine pancreas produces a variety of growth factors. To date, islet immunostaining has been shown for hepatocyte growth factor in the rat (TSUDA et al., 1992) , insulinlike growth factor 1 and 2 in humans and in the dog and rat (MAAKE and REINECKE, 1993) , transforming growth factor (TGF) /3-1, 8-2 and R-3 in humans (YAMANAKA et al., 1993) , and activin-A, a member of the TGF-R superf amily, in the rat (YASUDA et al., 1993) . Except for TGFs, which are distributed diffusely on all islet cells, those factors are localized to the A-cell population. The present study gives insights into aFGF as another candidate for a growth factor produced by A-cells.
We have demonstrated ultrastructural evidence of the localization of aFGF-like immunoreactivity in the secretory granules of A-cells. This is rather surprising in light of the biochemical fact that aFGF, as well as bFGF, lacks the signal peptide sequence necessary for the secretory pathway (BURGESSS and MACIAG, 1989) . This is the reason why we tentatively describe the present results in terms of "aFGF-like immunoreactivity".
However, to our knowledge, no other study has shown the subcellular localization of aFGF by electron microscopy.
Furthermore, the present study is the first to refer to aFGF in a typical gland cell population. It cannot be ruled out by past results, therefore, that aFGF-like immunoreactivity in the secretory granules of A cells indeed represents authentic aFGF. Alternatively, this immunoreactivity may be due to an unknown peptide with extensive sequence homology with aFGF.
AFGF belongs to a family of heparin-binding growth factors which currently consists of 7 members, i.e., aFGF, bFGF, Int-2 (FGF-3), Hst-1 (FGF-4), FGF-5, Hst-2 (FGF-6) and KGF (FGF-7) (BAIRD and KLAGSBRUN,1991) . The latter 5 members all have the signal peptide sequence, but their tissue distribution is largely unknown. It seems unlikely that the present anti-aFGF antiserum recognizes any of these 5 members, because it does not cross-react with bFGF, which has the highest peptide sequence homology (55%) with aFGF among the family members. However, there is a possibility that the islet A-cell contains an as yet unknown subtype of aFGF with a signal peptide sequence flanking the amino terminus. In any case, the present results suggest that aFGF (or its homolog) coexists with glucagon in the secretory granules of A-cell and is possibly released together with glucagon release. The biological role(s) of aFGF produced by A-cells can be considered in terms of its route of transportation as well as its target organ. On one hand, aFGF may be released into the blood stream in an endocrine manner and transported through the portal vein. In this regard, the liver may be considered as the primary target of aFGF. This organ itself is known to produce aFGF (KAN et al.,1989; MARSDEN et al., 1992) . Both the parenchyma) and mesenchymal cells of the liver are considered to be involved in aFGF synthesis, which may promote the proliferation of hepatocytes after a liver injury. The present study suggests a possibility that islet-derived aFGF contribute to liver regeneration. Alternatively, aFGF may primarily target the pancreatic acinar cells, because it is known that a special portal vein system connects islets directly with exocrine pancreatic tissue (OHTANI et al., 1986) . On the other hand, it is also possible that A-cell-derived aFGF may function as paracrine factor on the other cell populations of the islet, such as the B-and D-cells.
The present results also raise a possibility that aFGF is released from A cells in coincidence with release of glucagon, and plays a synergistic role with glucagon in the carbohydrate metabolism. In conjunction with this, a recent study has suggested that, in response to the feeding of rats, aFGF is secreted out of the walls of brain ventricles into the cerebrospinal fluid, and regulates the feeding behavior by affecting the function of glucose-sensitive hypothalamic neurons (HANAI et al., 1989; TOOYAMA et al., 1991) . It is interesting to consider, therefore, that islet aFGF may also participate in the regulation of the carbohydrate metabolism.
Finally, the present study has revealed the immunohistochemical localization of aFGF in the solitary endocrine cells of intestinal epithelia. The immuno-staining in these cells may be relatively low in intensity, as it is not detectable in paraffin sections. The distributional pattern of aFGF-positive cells, i.e., their absence in the stomach and duodenum and presence in the jejunum, ileum and colon, is consistent with that of L-cells (RAVAZZOLA et al., 1979) . The pre-and post-embedding immuno-electron microscopy demonstrates that aFGF-like immunoreactivity belongs to the L-cell, where it is localized primarily in the secretory granules. The L-cell was originally documented as having large granules similar to but slightly different from those of the pancreatic A-cell. Although L-cells are immunostained with antisera against glucagon, the major products of L-cells are glicentin and oxyntomodulin, which contain the full sequence of glucagon flanked by peptide extensions at the amino and carboxy termini (UNGER and ORCI, 1981) . It has been clarified that, in the A-and L-cells, the proglucagon molecule is processed into several structurally related peptides, including glucagon, glicentin, and oxyntomodulin as well as glucagon-like peptide-1 and -2 (Mojsov et al., 1986) . The biological role of glucagon-related peptides produced by L-cells is unknown. The present study demonstrates that aFGF is a common product of proglucagon-expressing cell populations. The function of intestinal aFGF may also be synergistic with glucagon-related peptides.
